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Abstract
Background: This work was to evaluate the perioperative safety and efficacy of cytoreductive surgery (CRS) plus
hyperthermic intraperitoneal chemotherapy (HIPEC) with lobaplatin and docetaxel in patients with peritoneal
carcinomatosis (PC) from gastrointestinal and gynecological cancers.
Methods: Patients were treated by CRS + HIPEC with lobaplatin 50 mg/m2 and docetaxel 60 mg/m2 in 6000 mL of
normal saline at 43 ± 0.5 °C for 60 min. Vital signs were recorded for 6 days after CRS + HIPEC procedures. Perioperative
serious adverse events (SAE), hematological, hepatic, renal, and electrolytes parameters, the changes in serum tumor
markers (TM) before and after operation, patient recovery, and overall survival (OS) were analyzed.
Results: One hundred consecutive PC patients underwent 105 CRS + HIPEC procedures and postoperative
chemotherapy. The median CRS + HIPEC duration was 463 (range, 245–820) min, and the highest temperature and heart
rate during six postoperative days were 38.6 °C (median 37.5 °C) and 124 bpm (median 100 bpm), respectively. The 30-
day perioperative SAE occurred in 16 (15.2 %) and mortality occurred in 2 (1.9 %) patients. Most routine blood laboratory
tests at 1 week after surgery turned normal. Among 82 cases with increased preoperative TM CEA, CA125, and CA199, 71
cases had TM levels reduced or turned normal. Median time to nasogastric tube removal was 5 (range, 3–23) days, to
liquid food intake 6 (range, 4–24) days, and to abdominal suture removal 15 (range, 10–30) days. At the median follow-
up of 19.7 (range, 7.5–89.2) months, the median OS was 24.2 (95 % CI, 15.0–33.4) months, and the 1-, 3-, and 5-year OS
rates were 77.5, 32.5, and 19.8 %, respectively. Univariate analysis identified five independent prognostic factors on OS:
the origin of PC, peritoneal cancer index, completeness of CRS, cycles of adjuvant chemotherapy, and SAE.
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Conclusions: CRS + HIPEC with lobaplatin and docetaxel to treat PC is a feasible procedure with acceptable safety and
can prolong the survival in selected patients with PC.
Trial registration: ClinicalTrials.gov, NCT00454519
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Background
The locoregional progression of gastrointestinal and
gynecological malignancies such as gastric cancer (GC),
colorectal cancer (CRC), ovarian cancer (OC), primary
peritoneum carcinomatosis (PPC), pseudomyxoma peri-
tonei (PMP), malignant peritoneal malignancies (MPM),
frequently results in peritoneal carcinomatosis (PC),
characterized by the presence of tumor nodules of
various size, number, and distribution on the peritoneal
surface, with significant negative impact on both survival
and quality of life, due to refractory ascites, progressive
intestinal obstruction, and unrelieved abdominal pain.
The traditional therapies for PC include systemic chemo-
therapy, palliative surgery, and best support care, without
any hope of cure. PC patients have a very poor prognosis
with median survival less than 6 months [1, 2].
With better understanding of the tumor biological be-
haviors and advances in treatment technologies, the
landscape of PC has changed remarkably, in that PC is
regarded as locoregional disease rather than widespread
terminal condition. Over the past decades, novel thera-
peutic approaches to PC have emerged, combining
cytoreductive surgery (CRS) plus hyperthermic intraperi-
toneal chemotherapy (HIPEC), which integrate the advan-
tages of surgically removing the bulky visible tumor
burden and regional hyperthermic chemotherapy eradicat-
ing micrometastases and invisible free cancer cells [3].
Hyperthermia and chemotherapy have synergistic ef-
fects, which is significantly enhanced at 42 °C [4–6]. The
chemotherapeutic regimens for HIPEC include cisplatin,
carboplatin, oxaliplatin, fluorouracil, mitomycin, pacli-
taxel and docetaxel, among others [7–9]. A study of
antitumor drugs has been conducted because of the suc-
cess of cisplatin. Forty years after the discovery of the
biological activity of cisplatin for the first time, oxalipal-
tin and carboplatin as routine chemotherapeutics are
widely used in clinical application today, while nedapla-
tin, heptaplatin, and lobaplatin have only been autho-
rized, respectively, in Japan, South Korea, and China
[10]. Though the response rate for first-line carboplatin
and paclitaxel is 70 to 80 %, this approach still yields
poor results and overall 5-year survival rate is less than
30 % [8]. Lobaplatin is a third-generation platinum
compound, which has demonstrated various advantages,
including potent antineoplastic activity, no significant
nephrotoxicity or neurotoxicity [11], no cross-resistance
with cisplatin [12], and relative molecular mass larger
than other platinum drugs with the advantage of
pharmacokinetics in intraperitoneal chemotherapy. Do-
cetaxel is a semisynthetic compound in the taxane class
of anticancer drugs. Although thought to operate
through the same mechanism of action as paclitaxel
by limiting microtubule depolymerization, the anti-
microtubule depolymerization capacity of docetaxel is
twice as much as paclitaxel. Moreover, docetaxel has
been found to have different spectra of activity and
incomplete cross-resistance.
Phase I/II clinical trials of lobaplatin in combination
with docetaxel have demonstrated acceptable safety and
efficacy for a variety of malignant solid tumors [13, 14].
Several basic researches have suggested that lobaplatin
and docetaxel prove synergistic antineoplastic effects
when used in combination [15]. Therefore, we summarize
the clinical results of CRS + HIPEC with lobaplatin and
docetaxel to treat PC at our center.
Methods
Patient selection
This study included 100 consecutive patients of PC
treated by 105 CRS + HIPEC procedures from January
2008 to June 2015, including 41 patients from CRC, 30
from GC, 16 from OC and PPC, and 13 from PMP.
Major clinicopathological characteristics of the patients
are listed in Table 1. The evaluations and major inclu-
sion and exclusion criteria were reported previously [16].
CRS + HIPEC procedure
A designated team of surgical oncologists, anesthesiolo-
gists, and operating room staff focusing on PC therapy per-
formed CRS + HIPEC procedure, with detailed description
reported previously [7, 16]. Before being anesthetized, the
Expression Sequential Compression System Vascular Refill
Detection device was wrapped to both legs of the patient
in order to prevent deep venous thrombosis because of
longer operation time. The abdominal exploration was
conducted under general anesthesia and stable
hemodynamic monitoring, through a midline xyphoid-
pubic incision. Once the abdominal wall was open, detailed
assessment of PC was carried out, recording the size and
distribution of tumor nodules, and the quantity and quality
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of ascites, to calculate the peritoneal cancer index (PCI) ac-
cording to the principle by Sugarbaker [17]. Then maximal
CRS was conducted to remove the primary and metastatic
tumor with acceptable margins, any involved adjacent
structures, regional lymph nodes, and peritonectomy
where peritoneal surfaces were involved by tumor [17].
The completeness of cytoreduction (CC score) was deter-
mined according to Sugarbaker’s criteria [18] before
HIPEC. CC-0 indicates no residual peritoneal disease after
CRS; CC-1 represents less than 2.5 mm of residual disease;
Table 1 Major clinicopathologic characteristics of the 100 PC
patients
Items Value, n (%)
Gender
Male/female 41 (41)/59 (59)
Age (years)
<60/≥60 71 (71)/29 (29)
Median KPS score (range) 70 (60–90)
Primary tumor
Carcinoma of the stomach 30 (30)
Carcinoma of the colorectum 41 (41)
Pseudomyxoma peritonei 13 (13)
Carcinoma of ovary and primary peritoneum 16 (16)
Histopathology
Adenocarcinoma, poorly/intermediately differentiated 44 (44)
Undifferentiated carcinoma 3 (3)
Myxoadenocarcinoma and signet-ring cell carcinoma 26 (26)
Serous adencarcinoma 14 (14)
Pseudomyxoma peritonei 13 (13)
Neoadjuvant chemotherapy
Yes/no 47 (47)/53 (53)
PC timinga
Synchronous/metachronous 80 (80)/20 (20)
PCI scoresa
≤20/>20 44 (44)/56 (56)
Median PCI scores (range) 22 (3–39)
Ascites at surgeryb
≤1000 mL/>1000 mL 63 (63)/37 (37)
Surgical procedures-organ resection
Partial/total gastrectomy 24 (24)
Resection of jejunum 4 (4)
Resection of ileum 12 (12)
Resection of ileocecus 32 (32)
Ascending colectomy 27 (27)
Transverse colectomy 32 (32)
Descending colectomy 12 (12)
Sigmoidectomy 16 (16)
Rectectomy 29 (29)
Resection ovarian/fallopian tube 29 (29)
Hysterectomy 15 (15)
Partial hepatectomy 2 (2)
Splenectomy 11 (11)
Cholecystectomy 11 (11)
Number of organ resecteda,c
1–3 resections 59 (67.1)
4–7 resections 23 (26.1)
8–12 resections 6 (6.8)
Table 1 Major clinicopathologic characteristics of the 100 PC
patients (Continued)
Peritonectomya
Greater/lesser omentum 92 (92)
Left diaphragmatic copula 15 (15)
Right diaphragmatic copula 38 (38)
Right colon gutter 41 (41)
Left colon gutter 42 (42)
Liver round ligament/sickle ligament 53 (53)
Douglas/rectovesical pouch 49 (49)
Anterior wall peritoneum 40 (40)
Pelvic peritoneum 58 (58)
Mesenteric fulguration 66 (66)
Peritoneal resection areaa
1–3 resections 44 (44)
4–6 resections 16 (16)






None or ostomy only 25 (25)
=1/>1 35 (35)/40 (40)
Postoperative chemotherapy moded
SC/SC + IP 31 (38.3)/50 (61.7)
Postoperative chemotherapy cycles
<6/≥6 49 (49)/51 (51)
Median postoperative chemotherapy cycles (range) 6 (1–12)
Median postoperative SC/IP + SC cycles (range)d 5 (1–12)/6 (1–12)
Median duration of ICU (hours) (range) 22 (11–94)
Median duration of hospitalization (days) (range) 20 (10–76)
Median follow-up (months) (range) 19.7 (7.5–89.2)
aAccording to the first surgery
bFive patients each underwent two operations
c12 patients without organ resection
d19 patients without any postoperative chemotherapy
PC peritoneal carcinomatosis, KPS Karnofsky performance score, PCI peritoneal
cancer index, CC completeness of cytoreduction, SC systemic chemotherapy,
IP intraperitoneal chemotherapy, ICU intensive care unit
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CC-2 means residual tumor between 2.5 mm and 2.5 cm;
and CC-3 indicates more than 2.5 cm of residual tumor or
the presence of a sheet of unresectable tumor nodules.
After CRS, abdominal cavity was sufficiently open by
Mediflex Surgical Products and all-layer surgical incision
protector covered the open abdomen in order to keep
the temperature stable and avoid chemotherapy drugs
diffusing into the air before HIPEC, because the open
coliseum technique was thought to provide optimal ther-
mal homogeneity and spatial diffusion [17], with 50 mg/
m2 of lobaplatin and 60 mg/m2 of docetaxel each dis-
solved in 3 L of saline. When the perfusion saline was
kept at 43.0 ± 0.5 °C and monitored with temperature
sensors on real time by an automatic hyperthermia
chemotherapy perfusion device (ES-6001, Wuhan E-sea
Digital Engineering, Wuhan, China), the perfusion solu-
tion was infused at a rate of 400 mL/min. The total
HIPEC time was 60 min. After HIPEC, the perfusion
solution in the peritoneal cavity was withdrawn by the
suction. Then the operation field was checked again for
any suspected mishaps. The anastomoses were made to
restore the continuity of the digestive tract. Routine col-
ostomy was not performed, but in patients with exten-
sive pelvic resections of the sigmoid colon, rectum,
uterus, and bladder, colostomy was made. Then drainage
tubes were placed at appropriate sites of anastomosis
and depending on the type of primary operation. The
incision was closed with a tension-reduced suture, and
patient was transferred to the intensive care unit (ICU)
for recovery.
Postoperative monitoring
All patients were carefully monitored for the following
parameters: (1) The changes in body temperature and
heart rate were recorded for 6 days after surgery; (2)
The complete peripheral blood routine, blood biochem-
ical parameters were examined on the first and seventh
postoperative days, and cardio-pulmonary function was
monitored, the change in serum tumor markers (TM)
before and after operation; (3) Anastomotic leakage,
intra-abdominal infection, hemorrhage, intestinal ob-
struction, and other life-threatening serious adverse
events (SAE); (4) Wound healing, including fat liquefac-
tion, incision split, surgical site infection, incisional her-
nia, time to suture, and drainage tube removal; (5)
Postoperative recovery of gastrointestinal and other or-
gans functions, including bowel sound, flatus passage,
defecation, time of removing nasogastric tube and urin-
ary catheter, and liquid food intake time; and (6) Survival
outcomes.
Postoperative chemotherapy and follow-up
Postoperative adjuvant chemotherapy included intra-
peritoneal chemotherapy (IP) through the IP port
mostly using lobaplatin (50 mg/m2, on day 1, every
21 days) and docetaxel (60 mg/m2, on day 1, every
21 days), and systemic chemotherapy (SC) mainly with
irinotecan, leucovorin, and 5-fluorouracil (FOLFIRI)
and oxaliplatin, leucovorin, and 5-fluorouracil (FOL-
FOX) regimens, all dosed according to body surface
area calculation [17, 19]. Platinum combined with do-
cetaxel was used in IP as had been proved to improve
OS for PC patients with acceptable safety [20]. IP
were given after the patients fully recovered from the
operation, and SC was delivered with IP synchron-
ously or alternately. Chemotherapy information was
listed in Table 1.
All patients underwent routinely postoperative follow-
up with physical examination, chest and abdominopelvic
computed tomography, full gastrointestinal contrast
media, and serum tumor markers (TM) every 3 months
during the first 2 years and then every 6 months there-
after by outpatient consultation or by telephone. The last
follow-up was on June 8, 2015, and the overall follow-up
rate was 100 %.
Statistical analysis and term definition
All data were obtained from a prospectively established
database of clinical records, surgical and pathology re-
ports, image examination and laboratory reports, and
follow-up records. And data were analyzed by SPSS soft-
ware for windows, version 19.0 (SPSS Inc., Chicago, IL,
USA), with P < 0.05 considered as statistically significant.
The numerical data were directly recorded, and the cat-
egory data were recorded into different categories.
The following study parameters were defined: (1) Peri-
operative period: from the day of CRS + HIPEC to day
30 postoperation; (2) Metachronous PC: after the pri-
mary tumor had been treated, the patients developed PC
during follow-up; (3) Synchronous PC: PC was diag-
nosed synchronously at first treatment; (4) PCI ≤20 was
defined as low PCI (LPCI), and PCI >20 was defined as
high PCI (HPCI) [18]; (5) The current research defined
CC0-1 as complete cytoreduction and CC2-3 as incom-
plete cytoreduction [18]; (6) Adverse events: the CRS +
HIPEC related complications during the perioperative
period, including SAE and other side effects; the former
mainly involved life-threatening complications such as
intestinal or anastomotic leakage, intestinal obstruction,
hemorrhage, and sepsis, and the latter included of
anemia, hepatic and renal toxicity, electrolyte disturb-
ance, hypoalbuminemia, myelosuppression, and delayed
wound healing, all on the basis of NCI Common Ter-
minology Criteria (CTC) for Adverse Events version 4.0
[21]; (7) Overall survival (OS): the time period from CRS
+ HIPEC to death as a result of disease for metachro-
nous PC; and the time period from first treatment of PC
to death due to synchronous PC.
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Results
A total of 100 PC patients were treated with 105 CRS +
HIPEC procedures, including five patients each receiving
two CRS + HIPEC procedures (all of five patients due to
tumor recurrence). There were 59 women and 41 men,
with a median age of 51 (range, 23–73) years. The me-
dian operation time was 463 (range, 245–820) min. Dur-
ing surgery, the median volume of blood loss, ascites,
and urine output were 600 (range, 100–4000) mL, 500
(range, 0–4200) mL, and 1200 (range, 200–3350) mL,
respectively, and the median transfusion volume of red
blood cells, plasma, cryoprecipitation and other fluids
were 600 (range, 0–3600) mL, 600 (range, 0–2350) mL,
150 (range, 0–300) mL, and 3500 (range, 300–13,500)
mL, respectively. In terms of organ resection, 59 patients
received removal of 1-3 organs segments, 23 patients
had excisions involving 4-7 organs segments, and 6 pa-
tients had resections involving 8–12 organs segments.
All patients underwent peritonectomy in more than one
area of the peritoneal and pelvic cavity (Table 1) and
stayed in ICU a median of 22 (range, 11–94) h.
Wound healing was successful in all but three pa-
tients who had fat liquefaction. The median time to
urinary catheter removal was 3 (range, 2–6) days, to
nasogastric tube removal 5 (range, 3–23) days, to fluid
food intake 6 (range, 4–24) days, to drainage tube re-
moval 9 (range, 5–69) days, to abdominal sutures re-
moval 15 (range, 10–30) days, and to hospital
discharge 20 (range, 10–76) days.
After operation, 30 patients received a median of 5
(range, 1–12) cycles of SC and 51 patients received a
median of 6 (range, 1–12) cycles of PIC + SC proce-
dures. The other patients did not receive adjuvant
chemotherapy due to intestinal leakage (n = 4), intestinal
obstruction (n = 2), acute myocardium infraction (n = 1),
and declining any chemotherapy (n = 12).
Vital signs during perioperative period
The body temperature and heart rate decreased grad-
ually to normal in a week after CRS + HIPEC, the num-
ber of patients with body temperature exceeding 37 °C
were 95, 57, 11, and 1 during the first 4 days after
operation (Table 2).
Laboratory results during perioperative period
The major laboratory results are listed in Table 3. One
week before CRS + HIPEC, TM increased in 82 (78.1 %)
of 105 CRS + HIPEC procedures, including cancer anti-
gen 125 (CA125) only increased in 23, carcinoembryonic
antigen (CEA) only increased in nine, and cancer anti-
gen 199 (CA199) only increased in three; CEA + CA125
increased in nine, CEA + CA199 increased in nine,
CA125 + CA199 increased in ten, and all these three in-
creased in 19. One week after CRS + HIPEC, CEA,
CA125, CA199, CEA + CA125, CEA + CA199, CA125 +
CA199, and CEA + CA125 + CA199 decreased or
returned to normal in 9, 21, 3, 9, 7, 5, 17, respectively,
and all of that in 71.
Survival analysis
At the median follow-up of 19.7 (range, 7.5–89.2)
months for all PC patients in this study, there were 55
(55 %) patients who died, 16 (16 %) survived with tumor,
and 29 (29 %) survived without tumor. The 1-, 3-, 5-year
OS rates were 77.5, 32.5, and 19.8 %, respectively. The
median OS was 24.2 (95 % CI, 15.0–33.4) months
(Fig. 1a). The OS comparisons were stratified based on
major clinicopathological factors (Table 4). Female pa-
tients, age ≥60 years, non-neoadjuvant chemotherapy,
synchronous PC, and ascites ≤1000 mL were factors for
better OS. The OS of PC patients from PMP, OC + PPC,
GC and CRC were not reached, 34.6 (95 % CI, 22.1–
47.1) months, 15.7 (95 % CI, 10.8–20.6) months, and
14.9 (95 % CI, 7.9–21.9) months (P = 0.000, log rank
test) (Fig. 1b), respectively. The median OS for LPCI vs.
HPCI was 46.1 (95 % CI, 10.7–81.5) vs. 16.3 (95 % CI,
8.6–24.0) months (P = 0.007, log rank test) (Fig. 2a). The
median OS for CC0-1 vs. CC2-3 was 42.9 (95 % CI,
28.3–57.5) vs. 13.6 (95 % CI, 10.6–15.6) months (P =
0.000, log rank test) (Fig. 2b). The median OS for post-
operative chemotherapy ≥6 vs. <6 cycles was 31.9 (95 %
CI, 24.1–39.7) months vs. 14.1 (95 % CI, 9.6–18.6)
months (P = 0.000, log rank test) (Fig. 2c). The median
OS for non-SAE vs. SAE was 31.2 (95 % CI, 20.5–41.9)
months vs. 12.2 (95 % CI, 9.5–15.0) months (P = 0.007,
log rank test) (Fig. 2d).
Serious adverse events (SAE)
SAE (grades 3–5) occurred in 16 (15.2 %) of 105 CRS +
HIPEC procedures (Table 5). Five patients developed
gastrointestinal obstruction, four gradually recovered by
active conservation remedy, and one with severe gastro-
plegia returned to normal gastrointestinal function
13 days after surgery. Four patients developed intestinal
Table 2 Important monitoring data of 100 PC patients with 105 CRS + HIPEC procedures during the 6 days after surgery
Index Range (median)
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6
Temperature (°C) 36.4–38.6 (37.5) 36.4–38.0 (37.0) 36.2–37.5 (36.5) 36.2–37.3 (36.5) 36.2–37.0 (36.5) 36.2–36.8 (36.5)
Heart rate (bpm) 76–124 (100) 65–120 (84) 62–120 (80) 60–90 (75) 60–84 (72) 60–84 (72)
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leakage. The first patient with generalized peritonitis
syndrome on postoperative day 4 received a reoperation
to repair the anastomosis on postoperative day 10 but
failed to repair the leakage and then turned to conserva-
tive treatment, the patient survived 2.2 months after the
surgery. The second patient developed serious gastric-
jejunum anastomosis fistula and sigmoid-rectum
anastomosis fistula on postoperative day 8, generalized
peritonitis, peritoneal abscess formation and septicemia
because of Staphylococcus aureus and Candida tropicalis
infection, with flushing abdominal cavity, intraperitoneal
drainage, antibiotics, and total parenteral nutrition sup-
port, the patient survived 2.3 months after the operation.
The third patient with generalized peritonitis syndrome
on postoperative day 11 then developed septicemia due
to gram-negative bacilli; given the above active conserva-
tive treatment, the patient survived 24 days after the sur-
gery. The fourth patient developed late-onset mild
anastomosis fistula on postoperative day 30 and received
conservative treatment; the patient survived 3 months
after the surgery.
Two patients developed severe diarrhea (grade 3) on
postoperative days 6 and 8, respectively, received anti-
diarrheal therapy, restoration of intestinal flora and elec-
trolytes supplementation therapy, and recovered after 15
and 20 days, respectively. Four patients developed septi-
cemia, two of whom were secondary to above anasto-
mosis leakage, and the other two patients were infected
with Candida parapsilosis, Enterococcus faecium on
postoperative days 10 and 9, respectively, received inten-
sified antiseptic treatments, and these two patients com-
pletely recovered in about 8 days. The last SAE case
developed acute myocardium infraction on postoperative
day 2 and the patient died.
Discussion
CRS + HIPEC as a comprehensive treatment strategy
makes the best of surgical resection, locoregional
Table 3 Blood profile and biochemical test results of 100 PC patients with 105 CRS + HIPEC procedures
Parameter Median (range) Normal
valueDay 1 Day 7
Peripheral blood test
Hemoglobin (g/L) 112.5 (66.0–155.0) 116.6 (84.5–151.0) 120–160
Red blood cell (×109/L) 3.96 (2.21–5.55) 3.9 (3.04–4.99) 4–5.5
White blood cell (×109/L) 9.37 (1.33–21.97) 7.74 (4.10–15.60) 4–10
Neutrophil count (×109/L) 8.6 (0.83–20.93) 5.73 (2.64–12.80) 2–7
Platelet count (×109/L) 177 (58–459) 213 (93–555) 100–300
Liver function tests
Aspartate aminotransferase (U/L) 37 (8–310) 13–51 (22) 0–46
Alanine aminotransferase (U/L) 36 (11–163) 20 (11–50) 0–46
Total bilirubin (μmol/L) 16.4 (4.5–56.6) 12.6 (5.5–24.8) 0–25
Direct bilirubin (μmol/L) 5.2 (0.3–38.2) 3.4 (0.1–11.1) 0–7
Indirect bilirubon (μmol/L) 10.5 (2.3–40.0) 9.5(3.3–20.0) 1.5–18
Total protein (g/L) 50.1 (31.9–67.2) 62.5 (46.8–75.8) 60–80
Albumin (g/L) 26.1 (10.8–44.3) 29.7–47.2 (38.6) 35–55
Globulin (g/L) 24 (10.4–35.1) 23 (13.8–36.6) 20–30
Gamma glutamyl transferase (g/L) 17 (5–132) 40 (10–154) 5–55
Alkaline phosphatase (U/L) 56 (11–135) 76 (36–154) 35–134
Renal function tests
Blood urea nitrogen (mmol/L) 3.7 (0.8–8.0) 4.8 (1.7–10.3) 1.7–7.2
Creatine (μmol/L) 50.5 (22.0–91.9) 56.9 (30.1–97.1) 45–117
Electrolytes
K+ (mmol/L) 3.68 (3.05–4.84) 4.35 (3.52–5.45) 3.5–5.5
Na+ (mmol/L) 136.4 (125.6–155.5) 138 (132.1–144.0) 135–145
Cl- (mmol/L) 102.3 (93.4–122.4) 100.9 (96.1–113.0) 96–106
Ca2+ (mmol/L) 1.91 (1.51–2.33) 2.15 (1.91–2.69) 2–2.7
Mg2+ (mmol/L) 0.85 (0.64–1.14) 0.96 (0.81–1.15) 0.85–1.15
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chemotherapy, hyperthermal therapy, and large volume
abdominal perfusion washing by CRS to remove the
peritoneal and abdominopelvic visible tumor, and the
synergistic effects of HIPEC to eradicate residual tumor
nodules, micrometastases, and free cancer cells. So far, it
is the most effective strategy to treat PC [22]. We have
launched experimental [23] and clinical [7, 16] studies to
prove the safety and effectiveness of CRS + HIPEC for
PC. The Netherlands Cancer Institute has proved in
colorectal PC patients the 70 % gain in overall survival
(22.4 months in the CRS + HIPEC group vs. 12.6 months
with standard palliative therapy) and recommends that
CRS + HIPEC be the standard treatment model for CRC
PC patients [22]. Spiliotis has conducted a phase III pro-
spective randomized study in recurrent epithelial ovarian
cancer and demonstrated that CRS + HIPEC could pro-
long OS nearly twice as much as single CRS (26.7 vs.
13.4 months) [24].
The peritoneal-plasma barrier limits the absorption
of large molecule-weight drugs by the peritoneum, en-
suring high concentration of drugs in the abdominal
perfusion solution. As a result, HIPEC increases the
direct cytotoxic effects of chemotherapeutic drugs on
peritoneal surface tumors and reduces the systemic
side effects. The mechanism of lobaplatin is similar to
that of other platinum drugs. Specifically, lobaplatin
induces the formation of inter-strand Pt-GG and Pt-
AG crosslinks, hindering DNA replication and tran-
scription ultimately inhibiting gene expression in
tumor cells [25]. Lobaplatin has shown encouraging
broad-spectrum anticancer activity against OC, CRC,
GC, lung cancer, breast cancer, and nasopharynx can-
cer [13–15, 26, 27]. Docetaxel is a semisynthetic com-
plex of the taxane class anti-tumor drugs. It binds to
free tubulin, accelerates the assembly of tubulin into
stable microtubules, and suppresses microtubule de-
polymerisation, blocks cell cycle in G-M phase, and
inhibits cell proliferation. Docetaxel is also a broad-
spectrum cytotoxic drug with potent effects on several
malignant solid tumors [28, 29]. A phase I clinical
trial demonstrated that lobaplatin combined with do-
cetaxel to treat human solid tumors could exhibit
short-term efficacy with a low incidence of SAE [13].
To achieve maximal CRS including organs and peri-
toneal areas resection, the field of operation should be
wide, increasing the risks for major complications. A
single-center large sample-size study on 243 PC patients
revealed a mortality rate 3 %, SAE rate 43 %, and the
SAEs mostly being intra-abdominal collection (40 %), in-
fection (38 %), pleural effusion (37 %), pneumothorax
(15.6 %), fistula (11.5 %), ileus (9.5 %), pneumonia
(7.4 %), bleeding (5.8 %), perforated viscus (5.8 %), pan-
creas leak (4.5 %), cardiac arrhythmias (4.1 %), and pul-
monary embolism (2.9 %) [30]. In this study, 16 (15.2 %)
SAEs occurred in 14 patients, and two of them died dur-
ing perioperative period, mortality and morbidity rates
being 1.9 and 15.2 %, respectively. Compared with litera-
ture reports, the SAE rate is relatively lower in our
study, possibly due to the following: (1) a designated
team performing CRS + HIPEC procedures; (2) the use
of broad-spectrum and strong antineoplastic HIPEC
drugs (lobaplatin 50 mg/m2 + docetaxel 60 mg/m2 for
60 min); (3) tension-reduced suture in closing abdominal
incision and abdominal wound caring every day to en-
sure proper wound healing; (4) transfusion of blood,
fresh-frozen plasma, cryoprecipitation, and albumin to
promptly restore hemostasis; (5) use effective broad-
spectrum antibiotics to cover gram-positive, gram-
Fig. 1 The Kaplan-Meier OS curves for the whole patients treated by CRS + HIPEC (a), and comparisons of OS among different primary diseases (b).
mo months, OC ovarian cancer, PPC primary peritoneum carcinomatosis, GC gastric cancer, CRC colorectal cancer, PMP pseudomyxoma peritonei, CRS
cytoreductive surgery, HIPEC hyperthermic intraperitoneal chemotherapy
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negative, anaerobic, and aerobic bacteria; (6) postopera-
tive ICU monitoring; and (7) good nutritional support
and quick restoration of electrolytes balance.
Detailed analysis of the 16 SAEs reveals the following
features: (1) more advanced clinical stages, with median
PCI 26 (range, 15–39); (2) more complex and difficult
operation procedures, with median organ resections,
areas of peritonectomy, CC, and operation time being 4
(range, 0–7), 8 (range, 1–10), 2 (range, 1–3), and
660 min (range, 250–760 min), respectively; (3) signifi-
cantly greater negative impact of SAEs on OS, with me-
dian OS of only 12.2 (95 % CI, 9.5–15.0) months for
SAEs vs. 31.2 (95 % CI, 20.5–41.9) months for non-
SAEs. Therefore, more attention should be paid to
selecting LPCI patients for CRS + HIPEC treatment,
and intensified perioperative care to minimize the risk
of SAEs.
In addition to routine hematological examination, the
detection of serum TM was necessary. In this study, 82
patients had elevated serum CEA, CA125, or CA199
levels before operation, and 71 cases (86.6 %) had post-
operative TM levels reduced or returned to normal. As
serum CEA, CA125, and CA199 levels could reflect
tumor invasiveness [31], peritoneal free tumor cells in
Table 4 OS comparisons stratified by major clinicopathological factors
Variables Number Median OS (mo) 95 % CI (mo) P
Gender 0.955
Male 41 22.7 6.2–39.2
Female 59 24.2 14.2–34.2
Age (year) 0.608
<60 71 22.7 13.4–32.0
≥60 29 25.9 7.0–44.8
Primary tumor 0.000
Carcinoma of the stomach 30 15.7 10.8–20.6
Carcinoma of the colorectum 41 14.9 7.9–21.9
Pseudomyxoma peritonei 13 Not reached Not reached
Carcinoma of ovary and primary peritoneum 16 34.6 22.1–47.1
Neoadjuvant chemotherapy 0.128
No 53 31.2 18.4–44.0
Yes 47 20.7 11.6–29.8
PC timing 0.086
Synchronous 80 27.5 18.1–36.9
Metachronous 20 13.2 10.6–15.8
PCI scores 0.000
≤20 44 46.1 10.7–81.5
>20 56 16.3 8.6–24.0
CC scores 0.000
0–1 63 42.9 28.3–57.5
2–3 37 13.6 10.6–15.6
Postoperative chemotherapy cycles 0.000
<6 49 14.1 9.6–18.6
≥6 51 31.9 24.1–39.7
SAE 0.007
No 86 31.2 20.5–41.9
Yes 14 12.2 9.5–15.0
Ascites 0.095
≤1000 mL 63 24.2 13.5–34.9
>1000 mL 37 21.2 4.8–37.7
In the original surgery calculation
OS overall survival, mo months
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the ascites [32], and proliferative activity of tumor cells
in ascites or primary tumor [33], respectively, the reduc-
tion of these TM could provide direct evidence that CRS
+ HIPEC is effective to control PC.
The median OS for the 100 patients was 24.2 (95 %
CI, 15.0–33.4) months, with the 1-, 3-, and 5-year sur-
vival rates being 77.5, 32.5, and 19.8 %, respectively.
From this study, several lines of evidence could be ob-
tained to support the comprehensive strategy for PC.
First, the median disease specific OS could reach 31.2
and 27.5 months for patients with non-neoadjuvant
chemotherapy and synchronous PC, but 20.7 and
13.2 months for those with neoadjuvant chemotherapy
and metachronous PC. Although such differences did
not reach statistical significance, possibly due to follow-
up time and sample size, the data do suggest that non-
neoadjuvant chemotherapy and synchronous PC could
obtain relatively better survival from the therapy.
Second, in terms of origin of PC, the PMP and OC PC
achieved better OS than the others. In our study, the
median OS of OC PC, GC PC, and CRC PC was 34.6,
15.7, and 14.9 months, respectively, similar to the litera-
ture reports of 26.7, 12.0, and 13.7 months [7, 16, 24],
respectively, suggesting that CRS + HIPEC with lobapla-
tin and docetaxel to treat PC can achieve acceptable
clinical outcome. Third, in terms of PCI, 56 % of the
total patients in this study had HPCI, and the median
OS was 16.3 (95 % CI, 8.6–24.0) months. The results
suggest that HPCI patients could still benefit from CRS
+ HIPEC rather than the traditional treatment with a
poor median survival of less than 6 months. However, it
was significantly shorter than the median OS of 46.1
(95 % CI, 10.7–81.5) months for LPCI. Fourth, in terms
of CC score, 63 % of PC patients with CC0-1 CRS
achieved a median OS of 42.9 (95 % CI, 28.3–57.5)
months, much longer than the median OS of 13.6 (95 %
Fig. 2 Kaplan-Meier survival curves. The statistical significance in overall survival (OS) comparisons stratified by PCI (a), CC (b), postoperative
adjuvant chemotherapy (c), and SAE (d). mo months, PCI peritoneal cancer index, CC completeness of cytoreduction, SAE serious adverse events
Wu et al. World Journal of Surgical Oncology  (2016) 14:246 Page 9 of 12







CC SAEs Interventionc OS (month)
Organ Peritoneal
Intestinal obstruction (n = 5, 4.8 %) F/45 Colon Met 24 2 9 1 1 CIO/AI CT 64.5, D
M/40 Colon Met 23 0 3 0 2 IIO/AI CT 12.2, D
F/23 Stomach Syn 30 1 2 2 2 CIO/AI CT 2.3, D
F/52 Colon Syn 15 0 8 0 1 IIO/AI CT 58.8, S
F/31 Colon Met 24 5 9 1 1 CIO/AI and combined gastroplegia CT 21.2, D
Intestinal leakage (n = 4, 3.8 %) F/26 Colon Syn 33 2 3 1 3 Limited peritonitis syndrome CT 12.6, D




M/24a Colon Syn 16 7 1 1 1 Generalized peritonitis syndrome CT 6.3, D
F/53 Ovary Syn 39 4 9 1 1 Generalized peritonitis syndrome reoperation 31.8, D
Septicemia (n = 4, 3.8 %) F/41 Stomach Met 18 0 5 0 2 Candida parapsilosis CT 14.1, S
F/40b Stomach Syn 28 5 9 3 2 Staphylococcus aureus and
Candida tropicalis septicemia
CT 5.5, D
M/24b Colon Syn 16 7 1 1 1 Gram-negative bacilli CT 6.3, D
M/64 Pseudomyxoma
peritonei
Syn 33 5 10 1 2 Enterococcus faecium infection CT 7.0, S
Diarrhea (n = 2, 1.9 %) F/62 Colon Met 25 6 7 2 3 Over 8 stools per day CT 6.0, D
F/64 Colon Met 24 3 6 2 3 Over 8 stools per day CT 11.1, D
Acute myocardium infarction
(n = 1, 0.9 %)
F/73 Colon Syn 26 6 9 2 1 Grades 5 CT 25.9, D
Common Terminology Criteria for Adverse Events version 4.0
aTwo patients died of SAE
bDifferent SAEs developed in the same patient
cAll patients recovered after intervention














CI, 10.6–15.6 months) for CC2-3 patients. Therefore,
every effort should be made to maximally reduce the
tumor burden. Fifth, adjuvant chemotherapy also plays a
key role in the comprehensive therapeutic strategy.
Appling IP + SC procedures obtains double effects on
PC nodules from a bidirectional approach, which have
been proved to improve survival [17, 20]. And 51 % of
PC patients with postoperative chemotherapy ≥6 cycles
reached median OS of 31.9 (95 % CI, 24.1–39.7) months,
much longer than the 14.1 (95 % CI, 9.6–18.6) months
for those with chemotherapy <6 cycles. These results
again support the notion that LPCI, CC0-1, postopera-
tive chemotherapy ≥6 cycles are independent factors for
OS benefit [2, 4, 7, 8, 16, 24].
To our knowledge, there have been three major publi-
cations on the combination of lobaplatin and docetaxel
in clinical setting [13, 14, 34]. One was the observational
study on patients with plural effusion or ascites [34].
The other two was phase I/II clinical trials on the safety
and efficacy of the two agents on a variety of solid tu-
mors. A phase I clinical trial demonstrated that lobapla-
tin (35 mg/m2) combined with docetaxel (60 mg/m2) to
treat human solid tumors (non-small cell lung cancer
11, small cell lung cancer 2, breast cancer 2, gastric
cancer 1, endometrial carcinoma 1) could exhibit short-
term efficacy (the response rate 7.1 %, the disease
control rate 78.6 %) and a low incidence of SAE, such as
leukopenia 30 % (grade 3), neutropenia 50 % (grades 3–
4) without non-hematological toxicities, with median
chemotherapy cycles of four (range, 1–6 cycles) [13].
This phase I study established that the maximal toler-
ated dose for this chemotherapy regimen is lobaplatin
35 mg/m2 combined with docetaxel 60 mg/m2, and this
regimen demonstrated broad-spectrum anti-tumor prop-
erties against lung cancer, breast cancer, endometrial
cancer, and gastric cancer. A phase II study evaluated
the clinical efficacy and safety of lobaplatin (30 mg/m2)
combined with docetaxel (75 mg/m2) on 39 patients
with recurrent or metastatic nasopharygenal carcinoma
[14]. This study demonstrated 61.5 % overall response
rate, 84.6 % disease control rate, and the median time of
progression 10 (95 % CI, 7.3–12.8) months. The most
common grade 3/4 toxicities included leucopaenia and
neutropenia 17.9 %, anemia 5.1 %, and increased amino-
transferase level 2.6 %. This study again demonstrated
that this lobaplatin-docetaxel combination is effective
against squamous cell carcinoma. A clinical observa-
tional study demonstrated that lobaplatin (20–30 mg/
m2) used in intrapleural or intraperitoneal infusion is a
safe and effective treatment for patients with malignant
pleural effusion or ascites from colorectal cancer or uter-
ine cancer [34]. Compared with these studies, our study
is the first to demonstrate that the lobaplatin-docetaxle
regimen used in HIPEC is safe and effective against
peritoneal carcinomatosis from colorectal cancer, gastric
cancer, ovarian cancer, primary peritoneal carcinoma,
and pseudomyxoma peritonei. Our dose (50 mg/m2 of
lobaplatin and 60 mg/m2 of docetaxel) used is compar-
able to those reported above. And the adverse events
were also comparable to the reported results.
Conclusions
CRS + HIPEC with lobaplatin and docetaxel to treat PC
is a feasible procedure with acceptable safety and can
prolong the OS of patients with PC from gastrointestinal
and gynecological malignancies.
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